Bilastine Tablet Uses & Treatment: Safe Daily Use and API Insights for Pharmaceutical Buyers

Last Updated: June 2026 | Reviewed based on current clinical approvals and pharmacopoeial standards

This guide is intended for pharmaceutical procurement professionals, formulation companies, and regulatory strategists. Information on dosing and clinical use references published prescribing information and SmPC guidance; it does not constitute medical advice.

Reviewed by Bio-Synth Regulatory Affairs & Quality Assurance Team. Prepared with inputs from professionals experienced in antihistamine API manufacturing, analytical quality control, and global regulatory documentation.

TL;DR: Bilastine is a second-generation H1-antihistamine approved for once-daily use in treating allergic rhinitis and urticaria. This article answers whether you can use it daily, covers key pharmacokinetic data, and provides a sourcing guide for B2B pharmaceutical buyers evaluating antihistamine APIs from India.

Introduction: Why Daily Antihistamine Treatment Is Increasing

Can we take bilastine every day? Yes. This second-generation antihistamine drug is commonly prescribed for daily use in the long-term treatment of allergic rhinitis and chronic urticaria. Its safety profile, low drug interaction risk, and minimal central nervous system effects make it suitable for extended use under medical supervision.

As global demand for non-sedating antihistamine APIs continues to rise, pharmaceutical buyers and procurement teams sourcing for regulated markets are increasingly evaluating Indian manufacturers. Bio-Synth, based in Hyderabad’s Balanagar Industrial Zone, supplies WHO-GMP certified, high-purity antihistamine drug substance to partners across regulated and semi-regulated markets.

Industry Insight: In recent procurement discussions, many formulation companies have shifted their supplier evaluation criteria from price alone to documentation readiness, regulatory compliance, and long-term supply reliability – particularly for antihistamine APIs entering European and MENA markets.

Clinical & Regulatory References

The clinical information presented in this article is based on published Bilastine prescribing information, peer-reviewed clinical studies, and international regulatory guidance for second-generation antihistamines. Pharmacokinetic data references the approved Summary of Product Characteristics (SmPC) and published pharmacology literature. Buyers should consult the applicable SmPC and local regulatory guidance for their target market.

What Is a Second-Generation H1-Antihistamine?

Bilastine (marketed as Bilaxten and under other trade names) is a selective H1-receptor antagonist classified as a second-generation antihistamine. As a non-sedating drug, it blocks histamine H1 receptors without causing the CNS depression associated with older first-generation antihistamines such as diphenhydramine or hydroxyzine.

The drug is indicated for the treatment of:

• Allergic rhinoconjunctivitis: Seasonal and perennial forms, including itchy eyes, sneezing, and nasal congestion.
• Chronic spontaneous urticaria: Including chronic idiopathic urticaria characterised by recurring hives and itch.

Its non-sedative nature, combined with a lack of clinically significant cardiac or hepatic interactions, sets this tablet formulation apart from older antihistamine treatments and supports its wide adoption in clinical care settings including hospitals and outpatient allergy clinics.

Can You Use Bilastine Every Day? Treatment for Chronic Allergic Conditions

Yes. The drug is commonly prescribed for daily use, especially in the management of chronic allergic conditions that require continuous symptom control. A doctor typically recommends a standard 20 mg once-daily dose for adults, with consistent therapeutic outcomes and a well-characterised side effects profile.

According to published clinical data and SmPC guidance:

• Continuous use up to 12 months has shown good tolerability in clinical trials.
• No significant cardiotoxicity, hepatotoxicity, or CNS interference has been reported.
• No evidence of tolerance build-up has been observed during regular daily administration.
• The drug does not require dose adjustment based on renal impairment in many patient populations.

For Pharmaceutical Buyers: Long-term daily prescription patterns directly influence API demand forecasting. Chronic urticaria and perennial rhinitis patients represent stable, year-round demand drivers for formulation companies sourcing antihistamine APIs.

Patients should always follow licensed indications, consult a doctor before initiating long-term use, and follow their doctor’s guidance on duration and dose. This article is for pharmaceutical sourcing purposes only.

Symptoms Managed with Once-Daily Dosing

Once-daily bilastine effectively controls the following symptoms across approved indications:

• Nasal congestion, rhinorrhoea, and itching in allergic rhinitis
• Ocular symptoms including itchy, watery, and red eyes in rhinoconjunctivitis
• Urticarial wheals, flare, and itch in chronic spontaneous urticaria
• Associated symptoms such as sneezing and post-nasal drip

Key Advantages of This Antihistamine Treatment for Allergic Rhinoconjunctivitis

This drug’s clinical profile supports broad use across patient populations. Key advantages for formulation companies and their end-markets include:

• Minimal sedation: Maintains cognitive function and care quality throughout the day.
• High H1 receptor selectivity: Reduces off-target activity and minimises drug interactions.
• No food restrictions: Maintains antihistamine treatment efficacy without dietary adjustments, when taken on an empty stomach as per label guidance.
• No significant liver metabolism: Suitable for patients with hepatic impairment under doctor supervision.
• Once-daily dosing: Supports patient adherence and care continuity.

Managing Symptoms in Elderly Patients and Paediatric Patients

The drug’s non-sedating profile and low CNS interaction make it particularly relevant for special populations:

• Elderly patients: Reduced risk of falls and cognitive impairment compared to first-generation antihistamines. A doctor should assess individual suitability based on polypharmacy risk.
• Paediatric patients: The tablet and oral solution formulations support use in children from age 2+ (at weight-appropriate doses) in several approved markets. Formulation companies developing paediatric presentations should consult local SmPC and regulatory guidance.

Pharmacokinetics of Bilastine Tablets at a Glance

Understanding the pharmacokinetic profile of bilastine tablets is essential for formulation scientists and regulatory strategists:

Pharmacokinetic data is based on published clinical studies and approved SmPC. Formulation-specific parameters may vary based on tablet excipient composition, manufacturing process, and dissolution profile. Buyers should consult their doctor or clinical team when designing generic bioequivalence studies.

Opportunities for API Buyers: Why Source from India?

India consistently ranks among the world’s top exporters of Active Pharmaceutical Ingredients. The antihistamine API segment is no exception, with increasing global demand and scalable manufacturing in Indian pharma hubs. Bio-Synth’s antihistamine API is manufactured to Indian Pharmacopoeia (IP) standard at our WHO-GMP certified facility in Hyderabad.

Hyderabad: A Leading Antihistamine API Hub

• Balanagar Industrial Area is home to WHO-GMP compliant facilities with strong analytical infrastructure.
• Bio-Synth leads in GMP-certified production of high-purity drug substance for regulated markets.
• Strong infrastructure supports efficient global distribution across hospitals, retail chains, and institutional buyers.

Regulatory Advantage

India’s regulatory ecosystem supports:

• WHO-GMP certification across manufacturing sites
• Cost-effective production without compromising drug product quality
• Export-ready documentation for 20+ global markets

Balanced View: While India remains a preferred sourcing destination, buyers should compare suppliers based on technical capabilities, audit history, documentation quality, and supply continuity in addition to manufacturing costs. A structured supplier scorecard reduces risk for long-term antihistamine API contracts.

What B2B Buyers Should Evaluate When Sourcing This Antihistamine API

Procurement Reality: Procurement teams commonly face challenges such as inconsistent batch quality, incomplete documentation, or long lead times when sourcing antihistamine APIs from suppliers without established quality systems. Identifying these risks during qualification protects regulatory timelines.

From Bio-Synth’s Experience: From our experience supplying this drug substance to formulation manufacturers, consistent control of assay purity, particle size distribution, and impurity levels plays an important role in supporting product quality and regulatory acceptance across different markets.

Key Considerations for Procurement Teams

• WHO-GMP Certification: Mandatory for global API export and regulated-market supply.
• DMF Availability: Drug Master File for FDA or EU regulatory submissions.
• Batch Consistency: Assay purity, impurity profile, and particle size distribution verified batch-to-batch.
• Stability Data: ICH Q1A-compliant long-term and accelerated stability data, including Zone IVb for tropical markets.
• Scalable Capacity: Confirmed ability to supply from pilot quantities through commercial tonnage.
• EHS Compliance: Environmental, Health, and Safety documentation as part of supplier qualification.

Regulatory Insight: Regulatory agencies increasingly evaluate suppliers on documentation integrity, change-control practices, analytical validation, and supply chain traceability in addition to product quality. For antihistamine tablet registrations, dissolution method validation and polymorphic form consistency are also evaluated.

Technical Compliance Checklist

Manufacturing Example: For tablet formulations, maintaining a consistent particle size distribution is particularly important to support uniform blending, compression performance, and finished drug product quality. Variations in particle size between batches can affect disintegration time, dissolution profile, and bioequivalence outcomes.

Buyer Guidance: Before approving a supplier, buyers should review analytical methods, stability data, impurity trends, packaging options, and long-term manufacturing capacity alongside commercial quotations. A supplier’s change-control history can also reveal process stability over time.

Documentation Transparency: Depending on customer qualification requirements, supporting documentation may include Certificates of Analysis (CoAs), stability summaries, manufacturing records, and applicable regulatory support documents — all subject to qualification procedures and confidentiality agreements.

Who Needs These Tablets? B2B Use Cases for Spontaneous Urticaria and Allergic Rhinitis

Global clinical demand patterns are evolving as this drug solidifies its place as both an OTC and prescription antihistamine. Formulation manufacturers are expanding their product range to include:

• Fixed-dose combinations (FDCs) with montelukast for allergic rhinitis management
• Chewable tablets and fast-disintegrating oral strips for improved patient care
• Paediatric oral suspensions and syrup formulations for younger patient populations
• Generic tablet launches in LATAM, ASEAN, Europe, and MENA markets post-patent expiry

India’s antihistamine API ecosystem is uniquely positioned to serve national retail brands across India and ASEAN, exporters to Europe and the Middle East, and WHO procurement programmes for allergy treatment protocols. For B2B buyers in hospitals networks and institutional allergy care, having a WHO-GMP certified, consistently documented supply chain is essential.

Lesson Learned: A common lesson across long-term API supply partnerships is that consistent documentation and reliable batch performance often contribute more to successful commercialisation than initial procurement cost alone.

Market Insight: Growing demand for paediatric formulations, fixed-dose combinations, and export-oriented generic products continues to reshape procurement priorities for antihistamine APIs. Formulation companies that secure compliant, scalable supply early gain a significant time-to-market advantage.

CDMO Advantage and Supply Chain Stability

With decades of experience in pharmaceutical manufacturing, Bio-Synth supports formulation companies across regulated and semi-regulated markets through reliable API manufacturing and CDMO services. Our track record spans multiple therapeutic categories – from antihistamines and antidiabetics to cardiovascular and CNS APIs.

Contract Development and Manufacturing Organisations that produce this drug substance benefit from:

• Vertical integration of intermediates: Bio-Synth’s advanced drug intermediates capability reduces supply chain dependency and improves process control.
• Speed-to-market capabilities: From lab scale to commercial batches with documented tech-transfer procedures.
• Packaging flexibility: HDPE drums, composite liners, and custom pack sizes for different market requirements.

Ongoing Support: Bio-Synth’s technical and regulatory teams support customers throughout supplier qualification, documentation review, technology transfer, and commercial supply — not just at the point of initial enquiry.

Bio-Synth supplies APIs and intermediates to pharmaceutical companies serving regulated and semi-regulated markets across multiple therapeutic segments.

Explore the Bio-Synth APIs list for the full range of GMP-compliant pharmaceutical ingredients, or review our quality certifications for WHO-GMP and ISO 9001:2015 documentation.

Scope & Disclaimer

This article is intended for educational and pharmaceutical sourcing purposes only. Decisions regarding antihistamine therapy should always follow approved prescribing information and guidance from a qualified healthcare professional or doctor. This content is not a substitute for medical advice, independent supplier qualification, or regulatory consultation.

Final Thoughts

While once-daily antihistamine treatment is safe and effective for chronic allergic conditions, its growing therapeutic footprint has opened significant doors for generic formulators and B2B procurement teams. Indian manufacturers — especially those in Hyderabad’s Balanagar zone — are well-positioned to meet global demand with WHO-GMP certified, technically documented drug substance.

With Bio-Synth’s decades of manufacturing heritage, WHO-GMP and ISO 9001:2015 certified facilities, and ICH Q7 GMP alignment, we ensure our partners can rely on consistent purity, regulatory documentation, and long-term supply continuity for antihistamine APIs across regulated and semi-regulated markets.

Bio-Synth continuously monitors developments in antihistamine APIs, international regulatory expectations, and formulation trends to support evolving customer requirements in this segment.

Partner with Bio-Synth for Validated API Supply

This article is intended as an educational resource for pharmaceutical professionals and should not replace independent medical advice or supplier qualification procedures.

Contact Bio-Synth today for validated antihistamine API, documentation support, and long-term CDMO partnerships. Browse our API catalogue or reach our technical sales team at info@bio-synth.com.

Commercial discussions and technical documentation requests are managed through secure business communication processes to protect customer confidentiality.

Frequently Asked Questions

Why do buyers trust Indian APIs for antihistamine supply?

India produces a significant share of global generic APIs, driven by WHO-GMP compliance, manufacturing scale, and competitive pricing. Hyderabad alone supplies APIs to over 100 countries with strong regulatory standing and efficient logistics infrastructure.

Is this antihistamine suitable for long-term daily use?

Yes. Clinical studies show continued safety and efficacy with minimal side effects during extended use. Always consult a doctor before initiating long-term antihistamine treatment, and follow the approved SmPC and licensed dose recommendations for your market.

Can I buy antihistamine API in bulk for B2B orders?

Yes. Bio-Synth supports B2B procurement online with complete CoAs, regulatory documentation, and international shipping support. Contact our team to initiate a qualified supplier relationship and request a commercial quotation.

What documentation should buyers request before qualifying an antihistamine API supplier?

Most procurement teams review the CoA, DMF (where applicable), stability data, impurity profile, analytical methods, and manufacturing quality certifications before supplier approval. Reviewing these documents during qualification — rather than after placing an order — significantly reduces the risk of delays during drug product regulatory submission.

What interactions should a doctor consider when prescribing this drug?

The drug has a low interaction profile. However, a doctor should consider its reduced bioavailability when taken with food or fruit juice, and evaluate potential interactions in patients on polypharmacy regimens. Prescribers are advised to consult the full SmPC for their approved product version.

This article is periodically reviewed to reflect evolving antihistamine therapeutics trends, API market developments, and regulatory expectations. Last reviewed: June 2026.